Showing 3751-3760 of 5333 results for "".
- DermTech Fills Three Leadership Postshttps://practicaldermatology.com/news/dermtech-fills-three-leadership-posts/2460843/With three new appointments, DermTech has filled key leadership roles at the company. Loren Clarke, MD is now Chief Medical Officer, Ray Bassi is Vice President, Sales, and Patrick Johnson is Vice President, Information Technology and Digital Systems. Dr. Clarke, a board-ce
- Skin of Color Update Event Expanding in 2021https://practicaldermatology.com/news/skin-of-color-update-event-expanding-in-2021/2460840/Skin of Color Update, a medical education event focused on the dermatologic treatment of patients with skin of color, is expanding in 2021 with an additional half day of programming and pre-conference symposium. The event will be held virtually September 10-12 with the symposium on August 3.
- FDA Approves StrataGraft for the Treatment of Adults with Thermal Burnshttps://practicaldermatology.com/news/fda-approves-stratagraft-for-the-treatment-of-adults-with-thermal-burns/2460839/The U.S. Food and Drug Administration approved StrataGraft for the treatment of adult deep partial thickness burns. "Serious burns can be an incredibly difficult injury to treat and can adversely affect more than just the skin. The goal of burn management is to help the patient ret
- Nutrafol Launches Postpartum Formulahttps://practicaldermatology.com/news/nutrafol-launches-postpartum-formula/2460838/The first-of-its-kind postpartum hair nutraceutical is now available from Nutrafol. Nutrafol Postpartum was developed with an OB/GYN to target the root causes of excess hair shedding and thinning post-pregnancy. It is intended to help the body recover from the physical stress of childbirth,
- Water's Edge Partners with Goodman Dermatologyhttps://practicaldermatology.com/news/waters-edge-partners-with-goodman-dermatology/2460837/Water’s Edge Dermatology has partnered with Goodman Dermatology, P.C., a general and cosmetic dermatology practice in Atlanta. Water’s Edge Dermatology recently merged with Riverchase Dermatology (collectively, “WED/RCD”) and is a leading provider of compreh
- Dermatologist Named as AMA President-Electhttps://practicaldermatology.com/news/dermatologist-named-as-ama-president-elect/2460835/Jack Resneck Jr, MD, a dermatologist from the San Francisco Bay Area, is the new president-elect of the American Medical Association (AMA). Following a year-long term as president-elect, Dr. Resneck will assume the office of AMA president in June 2022. “It is truly an honor t
- CellFX from Pulse Biosciences Cleared in Canadahttps://practicaldermatology.com/news/cellfx-from-pulse-biosciences-cleared-in-canada/2460833/The CellFX® System from Pulse Biosciences is now approved via a Medical Device License from Health Canada for use in dermatological procedures requiring ablation and resurfacing of the skin for the reduction, removal, and/or clearance of cellular-based benign lesions. Puls
- Nurx Adds Rosacea Care to List of Serviceshttps://practicaldermatology.com/news/nurx-adds-rosacea-care-to-list-of-services/2460832/Nurx, now includes rosacea treatment in its at-home dermatology services. The service consists of a consultation with a Nurx medical provider, a personalized treatment plan for rosacea, home delivery of medication, and ongoing care. The expansion builds on the successful launch of Nurx&
- Merz Aesthetics Launches New Online Aesthetics Education Platformhttps://practicaldermatology.com/news/merz-aesthetics-launches-new-online-aesthetics-education-platform/2460830/Merz Aesthetics is launching Merz Aesthetics Medical Forum, an online medical aesthetics education platform for health care professionals around the world. Established by Merz Aesthetics Global Medical Affairs, the Medical Forum provides on-demand content focused on medical aesthe
- EULAR: Data Show Benefit of Tremfya in PsA After Anti-TNF Failurehttps://practicaldermatology.com/news/eular-day-shown-benefit-of-tremfya-in-psa-after-anti-tnf-failure/2460834/New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Trem